Pharmaceutical Biotechnology de Michael J. Groves

Pharmaceutical Biotechnology

Michael J. Groves

Since the publication of the first edition of Pharmaceutical Biotechnology over a decade ago, a not-so-subtle shift in the meaning of the term "biotechnology" has occurred. It has come to mean something very specific, namely the development of drug substances with large protein and polypeptide molecules. These substances can be used as drugs in their own right but may also be used to manipulate cellular DNA in order to produce a required molecule that is believed to have desirable properties in the treatment of a disease. Accordingly, the second edition of this popular text reflects that change of definition by including new material that explores the development of these protein-based therapeutic substances.

See what's new in the Second Edition:

Expanded coverage of the formulation of proteins

Additional information on proteins used as drug delivery systems

Detailed discussion of interactions between proteins and phospholipids

Increased information on proteomics and gene therapy

Exploration of pulmonary administration and oral delivery of proteins

A broad review of vaccines

Discussion of genetic engineering and genomics

Challenges and issues involved in the development and the production of a drug

Citește tot Restrânge

Cuprins

Introduction. The Structure of Proteins. Recombinant DNA Basics. Monoclonal Antibodies. Proteomics: A New Emerging Area of Biotechnology. Commonly Used Analytical Techniques for Biotechnology Products. Proteins as Drug Delivery Systems. Formulation of Proteins and Peptides. Proteins and Phospholipids. Vaccines: Ancient Medicines to Modern Therapeutics. Pulmonary Drug Delivery System for Biomarcromolecule. Polymeric Systems for Oral Protein and Peptide Delivery. Regulatory and Compendial Issues. Some Challenges Relating to the future of Biopharmaceutical Technology.

Notă biografică

A pharmacist with a doctorate in chemical engineering, Dr. Groves has spent much of his career working in industry and academe. Now retired, his scientific interests include dispersed drug delivery systems and quality control issues for parenteral drug products. Editor or joint editor of a number of books, he has published 400 research papers, patents, reviews and book reviews. He is a Fellow of the Royal Pharmaceutical Society of Great Britain, the Institute of Biology and the American Association of Pharmaceutical Scientists.

Descriere

Edited by a world-renowned authority, with contributions from experts, this second edition explores the redefinition of the term biotechnology as applied to pharmaceuticals. The book examines the successful evolution of humanized monoclonal antibodies to treat rheumatoid arthritis and other diseases, considers the currently disappointing results of genetic engineering and genomics that have isolated disease-responsible genes without effect, and looks at the market and scientific reasons behind the failure of many biotechnology products to live up to their hype. It contains a discussion of regulatory and compendial issues and concludes with a look at future challenges facing biotechnology.